无放疗帕博利珠单抗联合化疗治疗PD-L1 TPS≥50%的局部晚期非小细胞肺癌(Evolution试验)
这项多中心、单臂、2期研究在日本9家机构纳入21例不可切除局部晚期NSCLC且PD-L1 TPS≥50%的患者,给予帕博利珠单抗联合铂类化疗、不做放疗。研究提示该方案可能是有前景的替代策略。
要点
- 不可切除局部晚期NSCLC且PD-L1 TPS≥50%患者,无放疗的帕博利珠单抗联合化疗2年PFS率为67%。
- 最常见≥3级不良事件为中性粒细胞减少(38%)、白细胞减少(19%)和肺炎(14%)。
- 7例(33%)发生严重不良事件,未报告治疗相关死亡。
核心结论
- 在不可切除局部晚期NSCLC且PD-L1 TPS≥50%患者中,帕博利珠单抗联合铂类化疗而不做放疗,可能提供可行且有前景的替代治疗策略。
研究设计与样本
- 前瞻性、多中心、单臂、2期研究(Evolution trial WJOG11819L),在日本9家机构开展。
- 纳入年龄≥20岁、组织学确诊不可切除局部晚期NSCLC且PD-L1 TPS≥50%、ECOG PS 0或1、至少一个可测量病灶、无既往系统治疗且器官功能充分者。
- 2020年5月18日至2022年2月22日共评估21例,全部入组;中位年龄73岁(IQR 68-80),男性16例(76%)。
- 主要终点为2年无进展生存率,在全分析集(符合入选标准且至少接受一剂研究治疗者)中评估。
主要发现
- 诱导期为帕博利珠单抗200 mg每3周联合铂类化疗4周期,后续帕博利珠单抗200 mg±培美曲塞500 mg/m2每3周维持至多2年。
- 21例中3例(14%)中止诱导治疗、18例(86%)完成;维持治疗期间8例(38%)中止、10例(48%)完成。
- 最常见≥3级不良事件为中性粒细胞减少8例(38%)、白细胞减少4例(19%)、肺炎3例(14%);严重不良事件7例(33%),未报告治疗相关死亡。
关键数值与推荐
- 诱导期方案:帕博利珠单抗200 mg每3周+顺铂75 mg/m2或卡铂(非鳞癌AUC 5、鳞癌AUC 6),联合培美曲塞500 mg/m2(非鳞癌)或白蛋白结合型紫杉醇100 mg/m2第1、8、15天(鳞癌),共4周期。
- 维持期方案:帕博利珠单抗200 mg±培美曲塞500 mg/m2每3周,至多2年。
- 主要终点2年无进展生存率67%(90% CI 46-83)。
临床怎么用
- 对不可切除局部晚期NSCLC且PD-L1 TPS≥50%、不适合或不愿接受放化疗的患者,可考虑无放疗的帕博利珠单抗联合铂类化疗方案。
- 治疗期间需重点监测中性粒细胞减少、白细胞减少和肺炎等不良事件。
局限性
- 单臂、2期设计,样本量仅21例,无随机对照,结论需更大样本验证。
- 研究仅在日本9家机构开展,种族和族裔数据未收集,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The standard of care for unresectable, locally advanced non-small-cell lung cancer (NSCLC) is chemoradiotherapy followed by durvalumab. This study (Evolution trial WJOG11819L) aimed to evaluate the efficacy and safety of radiotherapy-free pembrolizumab and chemotherapy in patients with unresectable, locally advanced NSCLC with a PD-L1 tumour proportion score (TPS) of 50% or higher. METHODS: This prospective, multicentre, single-arm, phase 2 study was conducted in nine institutes in Japan. Inclusion criteria were age 20 years or older, histologically confirmed unresectable, locally advanced NSCLC with a PD-L1 TPS of 50% or higher, an Eastern Cooperative Oncology Group performance status of 0 or 1, at least one measurable lesion, no previous systemic therapy, and adequate organ function. Patients received intravenous induction therapy comprising pembrolizumab 200 mg every 3 weeks plus platinum-based chemotherapy for four cycles: either cisplatin 75 mg/m2 or carboplatin (area under the curve [AUC] 5 for non-squamous NSCLC, AUC 6 for squamous NSCLC) plus pemetrexed 500 mg/m2 (non-squamous NSCLC) or nanoparticle albumin-bound paclitaxel 100 mg/m2 on days 1, 8, and 15 (squamous NSCLC). This was followed by maintenance therapy comprising intravenous pembrolizumab (200 mg) with or without intravenous pemetrexed (500 mg/m2) every 3 weeks for up to 2 years. The primary endpoint was 2-year progression-free survival and was assessed in the full analysis set (ie, all patients who met the eligibility criteria and received at least one dose of study treatment). The safety analysis set included all patients who received at least one dose of study treatment and had at least one post-treatment safety assessment. This trial was registered with ClinicalTrials.gov (NCT04153734) and is complete. FINDINGS: Between May 18, 2020, and Feb 22, 2022, 21 patients were assessed for eligibility and all were enrolled. Median age was 73 years (IQR 68-80); 16 (76%) patients were male; race and ethnicity data were not collected. Three (14%) patients discontinued and 18 (86%) patients completed the induction therapy; eight (38%) patients discontinued during maintenance therapy and ten (48%) patients completed the maintenance therapy. Median follow-up was 32·5 months (IQR 26·2-39·5). The 2-year progression-free survival rate was 67% (90% CI 46-83). The most common grade 3 or worse adverse events were neutropenia (eight [38%] of 21 patients), leukopenia (four [19%]), and pneumonia (three [14%]). Serious adverse events occurred in seven (33%) patients. No treatment-related deaths were reported. INTERPRETATION: These findings suggest that pembrolizumab combined with platinum-based chemotherapy, without radiotherapy, might provide a feasible and promising alternative treatment strategy for patients with unresectable, locally advanced NSCLC with a PD-L1 TPS of 50% or higher. FUNDING: Merck Sharp & Dohme.
引用
- Hata A, Ninomaru T, Okada H, et al. Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2025. PMID: 41082893. doi:10.1016/S1470-2045(25)00462-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。